Literature DB >> 31327051

Moderate-to-high intensity exercise with person-centered guidance influences fatigue in older adults with rheumatoid arthritis.

Daniel Kucharski1,2, Elvira Lange3,4, Alastair B Ross5,6, Sara Svedlund2,7, Caroline Feldthusen2,8,9, Karin Önnheim1, Kaisa Mannerkorpi2,8,9, Inger Gjertsson1,2,9.   

Abstract

Fatigue is described as a dominant and disturbing symptom of rheumatoid arthritis (RA) regardless of the advances in pharmacological treatment. Fatigue is also found to correlate with depression. The objective was to evaluate the impact of moderate-to-high intensity, aerobic and resistance exercise with person-centered guidance on fatigue, anxiety and depression, in older adults with RA. Comparisons were made between older adults (> 65 years) with RA taking part in a 20-week moderate-to-high intensity exercise at a gym (n = 36) or in home-based exercise of light intensity (n = 38). Assessments were performed at baseline, at 20 weeks, and at 52 weeks. Outcomes were differences in Multidimensional Fatigue Inventory (MFI-20), Visual Analog Scale Fatigue (VAS fatigue), and Hospital Anxiety and Depression Scale (HADS). Analysis of metabolomics was also performed. The subscales "physical fatigue" and "mental fatigue" in MFI-20 and symptoms of depression using HADS depression scale improved significantly at week 20 in the exercise group compared with the control group. Exercise did not influence global fatigue rated by VAS or subscales "reduced motivation", "reduced activity" and "general fatigue" in MFI-20. No significant change was found on the anxiety index of HADS. The improvements in physical fatigue were associated with changes in the metabolism of lipids, bile acids, the urea cycle and several sugars. Moderate-to-high intensity exercise with person-centered guidance decreased fatigue and improved symptoms of depression and were accompanied by metabolic changes in older adults with RA.

Entities:  

Keywords:  Anxiety; Arthritis; Depression; Exercise; Fatigue; Metabolomics; Patient-centered; Rheumatoid

Mesh:

Substances:

Year:  2019        PMID: 31327051     DOI: 10.1007/s00296-019-04384-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  43 in total

1.  Impact of fatigue on health-related quality of life in rheumatoid arthritis.

Authors:  Ines Rupp; Hendriek C Boshuizen; Catharina E Jacobi; Huibert J Dinant; Geertrudis A M van den Bos
Journal:  Arthritis Rheum       Date:  2004-08-15

2.  Fatigue in patients with rheumatoid arthritis: what is known and what is needed.

Authors:  H Repping-Wuts; P van Riel; T van Achterberg
Journal:  Rheumatology (Oxford)       Date:  2008-10-16       Impact factor: 7.580

3.  Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored.

Authors:  Sarah Hewlett; Zoë Cockshott; Margaret Byron; Karen Kitchen; Sue Tipler; Denise Pope; Maggie Hehir
Journal:  Arthritis Rheum       Date:  2005-10-15

4.  Plant sterols and endurance training combine to favorably alter plasma lipid profiles in previously sedentary hypercholesterolemic adults after 8 wk.

Authors:  Krista A Varady; Naoyuki Ebine; Catherine A Vanstone; William E Parsons; Peter J H Jones
Journal:  Am J Clin Nutr       Date:  2004-11       Impact factor: 7.045

5.  Fatigue in rheumatoid arthritis reflects pain, not disease activity.

Authors:  L C Pollard; E H Choy; J Gonzalez; B Khoshaba; D L Scott
Journal:  Rheumatology (Oxford)       Date:  2006-01-31       Impact factor: 7.580

Review 6.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review.

Authors:  Ingvar Bjelland; Alv A Dahl; Tone Tangen Haug; Dag Neckelmann
Journal:  J Psychosom Res       Date:  2002-02       Impact factor: 3.006

7.  Exercise treatment for depression: efficacy and dose response.

Authors:  Andrea L Dunn; Madhukar H Trivedi; James B Kampert; Camillia G Clark; Heather O Chambliss
Journal:  Am J Prev Med       Date:  2005-01       Impact factor: 5.043

Review 8.  Age, anemia, and fatigue.

Authors:  Matti S Aapro; David Cella; Martin Zagari
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

9.  Rheumatoid arthritis.

Authors:  Lars Klareskog; Anca Irinel Catrina; Stephen Paget
Journal:  Lancet       Date:  2009-01-20       Impact factor: 79.321

10.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors:  Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2003-01
View more
  5 in total

1.  Metabolites Associated With Fatigue and Physical Activity in Childhood Cancer.

Authors:  Janice S Withycombe; Ronald Eldridge; Yan Jin; Haiwai Gu; Sharon M Castellino; Dorothy D Sears
Journal:  Biol Res Nurs       Date:  2022-04-25       Impact factor: 2.318

2.  Long-time follow up of physical activity level among older adults with rheumatoid arthritis.

Authors:  Elvira Lange; Inger Gjertsson; Kaisa Mannerkorpi
Journal:  Eur Rev Aging Phys Act       Date:  2020-07-18       Impact factor: 3.878

Review 3.  Management of Fatigue in Rheumatoid Arthritis.

Authors:  Janet E Pope
Journal:  RMD Open       Date:  2020-05

4.  Effects of Locomotion Training on the Physical Functions and Quality of Life in Patients with Rheumatoid Arthritis: A Pilot Clinical Trial.

Authors:  Takeshi Mochizuki; Aiko Kurata; Koichiro Yano; Katsunori Ikari; Ken Okazaki
Journal:  Prog Rehabil Med       Date:  2022-03-29

5.  Moderate- to high intensity aerobic and resistance exercise reduces peripheral blood regulatory cell populations in older adults with rheumatoid arthritis.

Authors:  Sofia E M Andersson; Elvira Lange; Daniel Kucharski; Sara Svedlund; Karin Önnheim; Maria Bergquist; Elisabet Josefsson; Janet M Lord; Inga-Lill Mårtensson; Kaisa Mannerkorpi; Inger Gjertsson
Journal:  Immun Ageing       Date:  2020-05-16       Impact factor: 6.400

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.